Messina Carlo, Buzzatti Giulia, Dellepiane Chiara, Cavo Alessia, Tolomeo Francesco, Cattrini Carlo, Boccardo Francesco
aAcademic Unit of Medical Oncology, IRCCS San Martino University Hospital - IST National Cancer Research Institute bDepartment of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy.
Anticancer Drugs. 2016 Nov;27(10):917-43. doi: 10.1097/CAD.0000000000000405.
Genitourinary cancers represent a heterogeneous group of malignancies arising from genitourinary tract, and are responsible for almost 359 000 newly diagnosed cases and 58 420 related deaths in USA. Continuous advances in cancer genetics and genomics have contributed towards changing the management paradigms of these neoplasms. Neoangiogenesis, through the activation of the tyrosine-kinase receptors signalling pathways, represents the key mediator event in promoting tumour proliferation, differentiation, invasiveness and motility. In the last decade, several treatments have been developed with the specific aim of targeting different cell pathways that have been recognized to drive tumour progression. The following review attempts to provide a comprehensive overview of the literature, focusing on new advances in targeted therapies for genitourinary tumours. Furthermore, the promising results of the latest clinical trials and future perspectives will be discussed.
泌尿生殖系统癌症是起源于泌尿生殖道的一组异质性恶性肿瘤，在美国，每年有近35.9万例新诊断病例，58420例相关死亡。癌症遗传学和基因组学的不断进展推动了这些肿瘤治疗模式的改变。通过激活酪氨酸激酶受体信号通路的新生血管生成是促进肿瘤增殖、分化、侵袭和转移的关键介导事件。在过去十年中，人们开发了几种治疗方法，专门针对那些被认为会驱动肿瘤进展的不同细胞通路。以下综述旨在全面概述相关文献，重点关注泌尿生殖系统肿瘤靶向治疗的新进展。此外，还将讨论最新临床试验的喜人成果及未来展望。
